PSA and new biomarkers within multivariate models to improve early detection of prostate cancer

Cancer Letters

Volumn 249, Issue 1, 2007, Pages 18-29

  Stephan, Carsten ^a   Cammann, Henning ^a   Meyer, Hellmuth A ^a   Lein, Michael ^a   Jung, Klaus ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Artificial neural network; Logistic regression; Prostate biopsy; Prostate cancer; Prostate specific antigen; Receiver operating characteristic curve

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGE DISTRIBUTION; ARTIFICIAL NEURAL NETWORK; CANCER DIAGNOSIS; CLINICAL STUDY; DIGITAL RECTAL EXAMINATION; DISEASE MARKER; HUMAN; LOGISTIC REGRESSION ANALYSIS; MULTIVARIATE ANALYSIS; ORGAN SIZE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RISK FACTOR; SHORT SURVEY; TRANSRECTAL ULTRASONOGRAPHY;

EID: 33947285577     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2006.12.031     Document Type: Review

References (74)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., Smigal C., and Thun M.J. Cancer statistics, 2006. CA Cancer J. Clin. 56 (2006) 106-130
2. Polascik T.J., Oesterling J.E., and Partin A.W. Prostate specific antigen: a decade of discovery-what we have learned and where we are going. J. Urol. 162 (1999) 293-306
3. Bunting P.S. A guide to the interpretation of serum prostate specific antigen levels. Clin. Biochem. 28 (1995) 221-241
4. Brawer M.K. Prostate-specific antigen. Semin. Surg. Oncol. 18 (2000) 3-9
5. Nixon R.G., and Brawer M.K. Enhancing the specificity of prostate-specific antigen (PSA): an overview of PSA density, velocity and age-specific reference ranges. Br. J. Urol. 79 Suppl. 1 (1997) 61-67
6. Ukimura O., Durrani O., and Babaian R.J. Role of PSA and its indices in determining the need for repeat prostate biopsies. Urology 50 (1997) 66-72
7. Catalona W.J., Richie J.P., Ahmann F.R., Hudson M.A., Scardino P.T., Flanigan R.C., deKernion J.B., Ratliff T.L., Kavoussi L.R., and Dalkin B.L. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6630 men. J. Urol. 151 (1994) 1283-1290
8. Catalona W.J., Smith D.S., Ratliff T.L., Dodds K.M., Coplen D.E., Yuan J.J., Petros J.A., and Andriole G.L. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N. Engl. J. Med. 324 (1991) 1156-1161
9. Thompson I.M., Pauler D.K., Goodman P.J., Tangen C.M., Lucia M.S., Parnes H.L., Minasian L.M., Ford L.G., Lippman S.M., Crawford E.D., Crowley J.J., and Coltman Jr. C.A. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N. Engl. J. Med. 350 (2004) 2239-2246
10. Lilja H., Christensson A., Dahlen U., Matikainen M.T., Nilsson O., Pettersson K., and Lövgren T. Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin. Chem. 37 (1991) 1618-1625
11. Stenman U.H., Leinonen J., Alfthan H., Rannikko S., Tuhkanen K., and Alfthan O. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res. 51 (1991) 222-226
12. Catalona W.J., Smith D.S., Wolfert R.L., Wang T.J., Rittenhouse H.G., Ratliff T.L., and Nadler R.B. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 274 (1995) 1214-1220
13. Catalona W.J., Partin A.W., Slawin K.M., Brawer M.K., Flanigan R.C., Patel A., Richie J.P., deKernion J.B., Walsh P.C., Scardino P.T., Lange P.H., Subong E.N., Parson R.E., Gasior G.H., Loveland K.G., and Southwick P.C. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 279 (1998) 1542-1547
14. Partin A.W., Catalona W.J., Southwick P.C., Subong E.N., Gasior G.H., and Chan D.W. Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age. Urology 48 (1996) 55-61
15. Catalona W.J., Partin A.W., Finlay J.A., Chan D.W., Rittenhouse H.G., Wolfert R.L., and Woodrum D.L. Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4 ng/mL and digital rectal examination is not suspicious for prostate cancer: an alternative model. Urology 54 (1999) 220-224
16. Djavan B., Zlotta A., Kratzik C., Remzi M., Seitz C., Schulman C.C., and Marberger M. PSA, PSA density, PSA density of transition zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/mL. Urology 54 (1999) 517-522
17. Jung K., Stephan C., Elgeti U., Lein M., Brux B., Kristiansen G., Rudolph B., Hauptmann S., Schnorr D., and Loening S.A. Molecular forms of prostate-specific antigen in serum with concentrations of total prostate-specific antigen <4 μg/l - are they useful tools for early detection and screening of prostate cancer?. Int. J. Cancer 93 (2001) 759-765
18. Roehl K.A., Antenor J.A., and Catalona W.J. Robustness of free prostate specific antigen measurements to reduce unnecessary biopsies in the 2.6 to 4.0 ng/ml range. J. Urol. 168 (2002) 922-925
19. Raaijmakers R., Blijenberg B.G., Finlay J.A., Rittenhouse H.G., Wildhagen M.F., Roobol M.J., and Schroder F.H. Prostate cancer detection in the prostate specific antigen range of 2.0 to 3.9 ng/ml: value of percent free prostate specific antigen on tumor detection and tumor aggressiveness. J. Urol. 171 (2004) 2245-2249
20. Lee R., Localio A.R., Armstrong K., Malkowicz S.B., and Schwartz J.S. A meta-analysis of the performance characteristics of the free prostate-specific antigen test. Urology 67 (2006) 762-768
21. Lopez L.A., Gomez B.J., Marquez L.J., Leva V.M., Regueiro Lopez J.C., and Requena Tapia M.J. Determination of free prostatic specific antigen cut point for the selection of patients in first prostate biopsy. Acta Urol. Esp. 30 (2006) 13-17
22. Lee C.T., and Scardino P.T. Percent free Prostate-specific antigen for first-time prostate biopsy. Urology 57 (2001) 594-598
23. Stephan C., Lein M., Jung K., Schnorr D., and Loening S.A. Can prostate specific antigen derivatives reduce the frequency of unnecessary prostate biopsies? [Letter]. J. Urol. 157 (1997) 1371
24. Haese A., Graefen M., Noldus J., Hammerer P., Huland E., and Huland H. Prostatic volume and ratio of free-to-total prostate specific antigen in patients with prostatic cancer or benign prostatic hyperplasia. J. Urol. 158 (1997) 2188-2192
25. Mettlin C., Chesley A.E., Murphy G.P., Bartsch G., Toi A., Bahnson R., and Church P. Association of free PSA percent, total PSA, age, and gland volume in the detection of prostate cancer. Prostate 39 (1999) 153-158
26. Stephan C., Lein M., Jung K., Schnorr D., and Loening S.A. The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia. Cancer 79 (1997) 104-109
27. Lein M., Koenig F., Jung K., McGovern F.J., Skates S.J., Schnorr D., and Loening S.A. The percentage of free prostate specific antigen is an age-independent tumour marker for prostate cancer: establishment of reference ranges in a large population of healthy men. Br. J. Urol. 82 (1998) 231-236
28. Stephan C., Stroebel G., Heinau M., Lenz A., Roemer A., Lein M., Schnorr D., Loening S.A., and Jung K. The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of <4 ng/mL. Cancer 104 (2005) 993-1003
29. Carlson G.D., Calvanese C.B., and Partin A.W. An algorithm combining age, total prostate-specific antigen (PSA), and percent free PSA to predict prostate cancer: results on 4298 cases. Urology 52 (1998) 455-461
30. Virtanen A., Gomari M., Kranse R., and Stenman U.H. Estimation of prostate cancer probability by logistic regression: free and total prostate-specific antigen, digital rectal examination, and heredity are significant variables. Clin. Chem. 45 (1999) 987-994
31. Babaian R.J., Fritsche H., Ayala A., Bhadkamkar V., Johnston D.A., Naccarato W., and Zhang Z. Performance of a neural network in detecting prostate cancer in the prostate-specific antigen reflex range of 2 5 to 4.0 ng/mL. Urology 56 (2000) 1000-1006
32. Djavan B., Remzi M., Zlotta A., Seitz C., Snow P., and Marberger M. Novel artificial neural network for early detection of prostate cancer. J. Clin. Oncol. 20 (2002) 921-929
33. Finne P., Finne R., Auvinen A., Juusela H., Aro J., Maattanen L., Hakama M., Rannikko S., Tammela T.L., and Stenman U. Predicting the outcome of prostate biopsy in screen-positive men by a multilayer perceptron network. Urology 56 (2000) 418-422
34. Kalra P., Togami J., Bansal B.S.G., Partin A.W., Brawer M.K., Babaian R.J., Ross L.S., and Niederberger C.S. A neurocomputational model for prostate carcinoma detection. Cancer 98 (2003) 1849-1854
35. Stephan C., Jung K., Cammann H., Vogel B., Brux B., Kristiansen G., Rudolph B., Hauptmann S., Lein M., Schnorr D., Sinha P., and Loening S.A. An artificial neural network considerably improves the diagnostic power of percent free prostate-specific antigen in prostate cancer diagnosis: Results of a 5-year investigation. Int. J. Cancer 99 (2002) 466-473
36. Anagnostou T., Remzi M., Lykourinas M., and Djavan B. Artificial neural networks for decision-making in urologic oncology. Eur. Urol. 43 (2003) 596-603
37. Loch T., Leuschner I., Genberg C., Weichert-Jacobsen K., Kuppers F., Retz M., Lehmann J., Yfantis E., Evans M., Tsarev V., and Stockle M. Improvement of transrectal ultrasound. Artificial neural network analysis (ANNA) in detection and staging of prostatic carcinoma. Urologe A 39 (2000) 341-347
38. Lee H.J., Kim K.G., Lee S.E., Byun S.S., Hwang S.I., Jung S.I., Hong S.K., and Kim S.H. Role of Transrectal Ultrasonography in the Prediction of Prostate Cancer - Artificial Neural Network Analysis. J. Ultrasound Med. 25 (2006) 815-821
39. Romics I. The technique of ultrasound guided prostate biopsy. World J. Urol 22 (2004) 353-356
40. Partin, A.W., Murphy, G.P., Brawer, M.K. (2000) Report on prostate cancer tumor marker workshop 1999. Cancer; 88, 955-963.
41. Wei J.T., Zhang Z., Barnhill S.D., Madyastha K.R., Zhang H., and Oesterling J.E. Understanding artificial neural networks and exploring their potential applications for the practicing urologist. Urology 52 (1998) 161-172
42. Snow P.B., Smith D.S., and Catalona W.J. Artificial neural networks in the diagnosis and prognosis of prostate cancer: a pilot study. J. Urol. 152 (1994) 1923-1926
43. Horninger W., Bartsch G., Snow P.B., Brandt J.M., and Partin A.W. The problem of cutoff levels in a screened population. Cancer 91 (2001) 1667-1672
44. Sargent D.J. Comparison of artificial neural networks with other statistical approaches. Cancer 91 (2001) 1636-1642
45. Stephan C., Cammann H., Semjonow A., Diamandis E.P., Wymenga L.F.A., Lein M., Sinha P., Loening S.A., and Jung K. Multicenter evaluation of an artificial neural network to increase prostate cancer detection rate and reduce unnecessary biopsies. Clin. Chem. 48 (2002) 1279-1287
46. Remzi M., Anagnostou T., Ravery V., Zlotta A., Stephan C., Marberger M., and Djavan B. An artificial neural network to predict the outcome of repeat prostate biopsies. Urology 62 (2003) 456-460
47. Garzotto M., Hudson R.G., Peters L., Hsieh Y.C., Barrera E., Mori M., Beer T.M., and Klein T. Predictive modeling for the presence of prostate carcinoma using clinical, laboratory, and ultrasound parameters in patients with prostate specific antigen levels < or =10 ng/mL. Cancer 98 (2003) 1417-1422
48. Stephan C., Jung K., and Cammann H. Re: Predictive modeling for the presence of prostate carcinoma using clinical, laboratory, and ultrasound parameters in patients with prostate-specific antigen levels < or =10 ng/ml. Cancer 100 (2004) 1988-1990
49. Finne P., Finne R., Bangma C., Hugosson J., Hakama M., Auvinen A., and Stenman U.H. Algorithms based on prostate-specific antigen (PSA), free PSA, digital rectal examination and prostate volume reduce false-positive PSA results in prostate cancer screening. Int. J. Cancer 111 (2004) 310-315
50. Matsui Y., Utsunomiya N., Ichioka K., Ueda N., Yoshimura K., Terai A., and Arai Y. The use of artificial neural network analysis to improve the predictive accuracy of prostate biopsy in the Japanese population. Jpn. J. Clin. Oncol. 34 (2004) 602-607
51. Blijenberg B.G., Yurdakul G., Van Zelst B.D., Bangma C.H., Wildhagen M.F., and Schroder F.H. Discordant performance of assays for free and total prostate-specific antigen in relation to the early detection of prostate cancer. BJU. Int. 88 (2001) 545-550
52. Jung K., Stephan C., Lein M., Henke W., Schnorr D., Brux B., Schürenkämper P., and Loening S.A. Analytical performance and clinical validity of two free prostate-specific antigen assays compared. Clin. Chem. 42 (1996) 1026-1033
53. Kort S.A., Martens F., Vanpoucke H., van Duijnhoven H.L., and Blankenstein M.A. Comparison of 6 automated assays for total and free prostate-specific antigen with special reference to their reactivity toward the WHO 96/670 reference preparation. Clin. Chem. 52 (2006) 1568-1574
54. Semjonow A., Oberpenning F., Brandt B., Zechel C., Brandau W., and Hertle L. Impact of free prostate-specific antigen on discordant measurement results of assays for total prostate-specific antigen. Urology 48 Suppl. (1996) 10-15
55. Stephan C., Klaas M., Muller C., Schnorr D., Loening S.A., and Jung K. Interchangeability of measurements of total and free prostate-specific antigen in serum with 5 frequently used assay combinations: an update. Clin. Chem. 52 (2006) 59-64
56. Soletormos G., Semjonow A., Sibley P.E., Lamerz R., Petersen P.H., Albrecht W., Bialk P., Gion M., Junker F., Schmid H.P., and Van Poppel H. Biological variation of total prostate-specific antigen: a survey of published estimates and consequences for clinical practice. Clin. Chem. 51 (2005) 1342-1351
57. Yurdakul G., Bangma C., Blijenberg B., van Zelst B., Wildhagen M., van der K.T., and Schroder F. Different PSA Assays Lead to Detection of Prostate Cancers with Identical Histological Features. Eur. Urol. 42 (2002) 154
58. Link R.E., Shariat S.F., Nguyen C.V., Farr A., Weinberg A.D., Morton R.A., Richardson B., Bernard D., and Slawin K.M. Variation in prostate specific antigen results from 2 different assay platforms: clinical impact on 2304 patients undergoing prostate cancer screening. J. Urol. 171 (2004) 2234-2238
59. C. Stephan, C. Xu, H. Cammann, M. Graefen, A. Haese, H. Huland, A. Semjonow, E.P. Diamandis, M. Remzi, B. Djavan, M.F. Wildhagen, B.G. Blijenberg, P. Finne, U.H. Stenman, K. Jung, H.A. Meyer, Assay-specific artificial neural networks for 5 different sa assays and populations with PSA 2-10 ng/ml in 4480 men, World J. Urol, 2007, in press.
60. Stamey T.A., Caldwell M., McNeal J.E., Nolley R., Hemenez M., and Downs J. The prostate specific antigen era in the United States is over for prostate cancer: What happened in the last 20 years?. J. Urol. 172 (2004) 1297-1301
61. Chun F.K., Graefen M., Briganti A., Gallina A., Hopp J., Kattan M.W., Huland H., and Karakiewicz P.I. Initial biopsy outcome prediction - head-to-head comparison of a logistic regression-based nomogram versus artificial neural network. Eur. Urol. (2006) available online 4 August, doi10.1016/j.eururo.2006.07.021
62. C. Stephan, H.A. Meyer, H. Cammann, M. Lein, S.A. Loening, K. Jung, Re: Chun FK, Graefen M, Briganti A et al. Initial biopsy outcome prediction - head-to-head comparison of a logistic regression-based nomogram versus artificial neural network, Eur. Urol., 2007, in press, doi:10.1016/j.eururo.2006.07.021.
63. Stephan C., Jung K., and Sinha P. Tumor markers for prostatic cancer - which way in this millenium?. Res. Adv. Cancer 2 (2002) 147-157
64. Partin A.W., Catalona W.J., Finlay J.A., Darte C., Tindall D.J., Young C.Y., Klee G.G., Chan D.W., Rittenhouse H.G., Wolfert R.L., and Woodrum D.L. Use of human glandular kallikrein 2 for the detection of prostate cancer: preliminary analysis. Urology 54 (1999) 839-845
65. Becker C., Piironen T., Pettersson K., Björk T., Wojno K.J., Oesterling J.E., and Lilja H. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum. J. Urol. 163 (2000) 311-316
66. Magklara A., Scorilas A., Catalona W.J., and Diamandis E.P. The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA. Clin. Chem. 45 (1999) 1960-1966
67. Nam R.K., Diamandis E.P., Toi A., Trachtenberg J., Magklara A., Scorilas A., Papnastasiou P.A., Jewett M.A., and Narod S.A. Serum human glandular kallikrein-2 protease levels predict the presence of prostate cancer among men with elevated prostate-specific antigen. J. Clin. Oncol. 18 (2000) 1036-1042
68. Stephan C., Jung K., Soosaipillai A., Yousef G.M., Cammann H., Meyer H., Xu C., and Diamandis E.P. Clinical utility of human glandular kallikrein 2 within a neural network for prostate cancer detection. BJU Int. 96 (2005) 521-527
69. Stephan C., Xu C., Brown D.A., Breit S.N., Michael A., Nakamura T., Diamandis E.P., Meyer H., Cammann H., and Jung K. Three new serum markers for prostate cancer detection within a percent free PSA-based artificial neural network. Prostate 66 (2006) 651-659
70. Nakamura T., Scorilas A., Stephan C., Jung K., Soosaipillai A.R., and Diamandis E.P. The usefulness of serum human kallikrein 11 for discriminating between prostate cancer and benign prostatic Hyperplasia. Cancer Res. 63 (2003) 6543-6546
71. Brown D.A., Stephan C., Ward R.L., Law M., Hunter M., Bauskin A.R., Amin J., Jung K., Diamandis E.P., Hampton G.M., Russell P.J., Giles G.G., and Breit S.N. Measurement of serum levels of macrophage inhibitory cytokine 1 combined with prostate-specific antigen improves prostate cancer diagnosis. Clin. Cancer Res. 12 (2006) 89-96
72. Meyer-Siegler K.L., Bellino M.A., and Tannenbaum M. Macrophage migration inhibitory factor evaluation compared with prostate specific antigen as a biomarker in patients with prostate carcinoma. Cancer 94 (2002) 1449-1456
73. Stephan C., Meyer H.A., Cammann H., Nakamura T., Diamandis E.P., and Jung K. Improved prostate cancer detection with a human kallikrein 11 and percentage free PSA-based artificial neural network. Biol. Chem. 387 (2006) 801-805
74. Stephan C., Meyer H.A., Kwiatkowski M., Recker F., Cammann H., Loening S.A., Jung K., and Lein M. A (-5,-7) ProPSA based artificial neural network to detect prostate cancer. Eur. Urol. 50 (2006) 1014-1020